JP7492507B2 - Ｇｌｐ－１受容体アンタゴニスト - Google Patents

Ｇｌｐ－１受容体アンタゴニスト Download PDF

Info

Publication number
JP7492507B2
JP7492507B2 JP2021520179A JP2021520179A JP7492507B2 JP 7492507 B2 JP7492507 B2 JP 7492507B2 JP 2021520179 A JP2021520179 A JP 2021520179A JP 2021520179 A JP2021520179 A JP 2021520179A JP 7492507 B2 JP7492507 B2 JP 7492507B2
Authority
JP
Japan
Prior art keywords
zwitterion
tautomeric
salt
compound
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021520179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504798A5 (https=
JP2022504798A (ja
Inventor
ブラウン，ジャイルズ・アルバート
コングリーヴ，マイルズ・スチュアート
スカリー，コナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of JP2022504798A publication Critical patent/JP2022504798A/ja
Publication of JP2022504798A5 publication Critical patent/JP2022504798A5/ja
Application granted granted Critical
Publication of JP7492507B2 publication Critical patent/JP7492507B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021520179A 2018-10-12 2019-10-14 Ｇｌｐ－１受容体アンタゴニスト Active JP7492507B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1816639.7A GB201816639D0 (en) 2018-10-12 2018-10-12 GLP-1 Receptor Antagonist
GB1816639.7 2018-10-12
PCT/GB2019/052915 WO2020074927A2 (en) 2018-10-12 2019-10-14 Glp-1 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2022504798A JP2022504798A (ja) 2022-01-13
JP2022504798A5 JP2022504798A5 (https=) 2022-10-24
JP7492507B2 true JP7492507B2 (ja) 2024-05-29

Family

ID=64397527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520179A Active JP7492507B2 (ja) 2018-10-12 2019-10-14 Ｇｌｐ－１受容体アンタゴニスト

Country Status (8)

Country Link
US (2) US12441777B2 (https=)
EP (1) EP3863661A2 (https=)
JP (1) JP7492507B2 (https=)
CN (1) CN113166206A (https=)
AU (1) AU2019358324B2 (https=)
CA (1) CA3115448A1 (https=)
GB (1) GB201816639D0 (https=)
WO (1) WO2020074927A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202011604D0 (en) * 2020-07-27 2020-09-09 Heptares Therapeutics Ltd GLP-1 receptor antagonists
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526899A (ja) 2005-01-14 2008-07-24 ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド 修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
WO2011027738A1 (ja) 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
CN102532301A (zh) 2010-12-31 2012-07-04 上海医药工业研究院 一类新型的Exendin-4类似物及其制备方法
JP2016532705A (ja) 2013-08-29 2016-10-20 ケミカル アンド バイオファーマシューティカル ラボラトリーズ オブ パトラ エス．エー． アミノ二酸含有ペプチド修飾剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
WO2007139941A2 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
WO2010032509A1 (ja) * 2008-09-20 2010-03-25 国立大学法人京都大学 膵島イメージング用分子プローブ前駆体及びその使用
WO2010120476A2 (en) 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
US9278146B2 (en) * 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
LT3297653T (lt) * 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526899A (ja) 2005-01-14 2008-07-24 ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド 修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
WO2011027738A1 (ja) 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
CN102532301A (zh) 2010-12-31 2012-07-04 上海医药工业研究院 一类新型的Exendin-4类似物及其制备方法
JP2016532705A (ja) 2013-08-29 2016-10-20 ケミカル アンド バイオファーマシューティカル ラボラトリーズ オブ パトラ エス．エー． アミノ二酸含有ペプチド修飾剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEURER, Janet A. et al.，Metabolism，1999年，Vol. 48, No. 6，pp. 716-724
MONTROSE-RAFIZADEH, Chahrzad et al.，The Journal of Biological Chemistry，1997年，Vol. 272, No. 34，pp. 21201-21206

Also Published As

Publication number Publication date
AU2019358324B2 (en) 2025-05-22
AU2019358324A1 (en) 2021-04-22
CA3115448A1 (en) 2020-04-16
US12441777B2 (en) 2025-10-14
CN113166206A (zh) 2021-07-23
US20250368709A1 (en) 2025-12-04
US20210355186A1 (en) 2021-11-18
GB201816639D0 (en) 2018-11-28
WO2020074927A2 (en) 2020-04-16
JP2022504798A (ja) 2022-01-13
WO2020074927A3 (en) 2020-12-17
EP3863661A2 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
AU2007319066B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
TWI770781B (zh) Gip/glp1共促效劑化合物
JP5755653B2 (ja) ペプチド性ｇｌｐ−２アゴニスト
US20250368709A1 (en) Glp-1 receptor antagonists
WO2024149080A1 (zh) 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
JP2023535476A (ja) Ｇｌｐ－１受容体アンタゴニスト
JP7812338B2 (ja) Ｇｌｐ受容体アゴニスト
AU2021236951A1 (en) Oral GLP receptor agonists
ES2274268T3 (es) Compuestos y composiciones para el tratamiento de la diabetes y trastornos relacionados con la diabetes.
RU2838225C1 (ru) Агонисты рецепторов glp
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
WO2026073030A1 (en) Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240517

R150 Certificate of patent or registration of utility model

Ref document number: 7492507

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350